source
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…
- Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thicketsIndustry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…